








Patterns of Psychiatric Comorbidity and Genetic
Correlations Provide New Insights Into
Differences Between Attention-Deficit/
Hyperactivity Disorder and Autism
Spectrum Disorder
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Jan Haavik, and Kari KlungsøyrISSABSTRACT
BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) share common
genetic factors but seem to have specific patterns of psychiatric comorbidities. There are few systematic studies on
adults; therefore, we compared psychiatric comorbidities in adults with these two neurodevelopmental disorders
using population-based data and analyzed their genetic correlations to evaluate underlying factors.
METHODS: Using data from Norwegian registries, we assessed patterns of psychiatric disorders in adults with ADHD
(n = 38,636; 2.3%), ASD (n = 7528; 0.4%), and both diagnoses (n = 1467; 0.1%) compared with the remaining adult
population (n = 1,653,575). We calculated their prevalence ratios (PRs) and differences using Poisson regression, also
examining sex-specific relations. Genetic correlations (rg) among ADHD, ASD, and the examined psychiatric disorders
were calculated by linkage disequilibrium score regression, exploiting summary statistics from relevant genome-wide
association studies.
RESULTS: For all psychiatric comorbidities, PRs differed between ADHD and ASD. Associations were strongest in
individuals with ADHD and ADHD1ASD for most comorbidities, in both men and women. The relative prevalence
increase of substance use disorder was three times larger in ADHD than in ASD (PRADHD, 6.2; 95% confidence in-
terval [CI], 6.1–6.4; PRASD, 1.9; 95% CI, 1.7–2.2; p , .001); however, the opposite was true for schizophrenia (PRASD,
13.9; 95% CI, 12.7–15.2; PRADHD, 4.4; 95% CI, 4.1–4.7; p , .001). Genetic correlations supported these patterns but
were significantly different between ADHD and ASD only for the substance use disorder proxies and personality traits
(p , .006 for all).
CONCLUSIONS: Adults with ADHD, ASD, or both ADHD and ASD have specific patterns of psychiatric comorbidities.
This may partly be explained by differences in underlying genetic factors.
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https://doi.org/10.1016/j.biopsych.2019.04.021Attention-deficit/hyperactivity disorder (ADHD) and autism
spectrum disorder (ASD) are highly heritable neuro-
developmental conditions and major contributors to human
suffering worldwide (1,2). There is emerging evidence of
polygenicity and environmental factors contributing to both
disorders (3,4). Genetic, epidemiological, and twin studies
show that ADHD and ASD often co-occur and share com-
mon underlying genetic factors (5–8), but with different
phenotypic characteristics. The shared genetic factors are
believed to affect the structure and function of molecular
networks in the brain, possibly involved in the etiology of
ADHD (9) and ASD (10).SEE COMMENTARY
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N: 0006-3223 BiologIndividuals with either ADHD or ASD have a 65% to 90%
risk of developing concomitant psychiatric disorders (11–13),
but with seemingly different patterns of comorbidity. Adults
with ASD present high rates of co-occurring anxiety, depres-
sion (13), bipolar disorder (BD), and schizophrenia spectrum
disorder (SCZ) (14–16), while adult ADHD is reported to co-
occur with anxiety disorder and major depressive disorder
(MDD) (17–19), BD (11,19–22), personality disorders (PDs)
(18,19,23), SCZ, (19,22,24,25), and substance use disorder
(SUD) (19,20,26).
ADHD and ASD share genetic factors with the above-
mentioned psychiatric disorders (27), and significant geneticON PAGE e25
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50 Yearscorrelations between different phenotype-specific traits for
ADHD and ASD have been demonstrated (28).
Nonetheless, except for a couple of small clinical studies,
patterns of psychiatric comorbidities have not been system-
atically compared between adults with ASD or ADHD (29,30).
Further, previous studies have reported that children with both
ADHD and ASD may have more severe impairments than those
with ASD alone; however, comparable studies in adults are
lacking (31,32). Only one single population-based study has
directly compared individuals with ADHD alone, ASD alone, or
both ADHD and ASD with unaffected individuals, but this was
in a population too young to be diagnosed with adult-onset
psychiatric disorders (33).
We aimed at evaluating similarities and differences in psy-
chiatric comorbidity between ADHD and ASD in adulthood,
both clinically and genetically. Therefore, we compared the
prevalence of psychiatric disorders in adults with ADHD alone,
ASD alone, and both ADHD and ASD with adults without
ADHD or ASD and supplemented these analyses with the




We conducted cross-sectional analyses in a cohort of adults
by linking information from four nationwide, population-based
registries, all with compulsory notification: the Medical Birth
Registry of Norway, established in 1967 (34); the Norwegian
Prescription Database (NorPD) (35), established in 2004; the
Norwegian Patient Registry (NPR) (36), with data since 2008;
and the National Educational Database from Statistics Norway
(37,38) (see Supplement for more details).
Individual records from the registries were linked by means
of the unique national identification numbers, given to all in-
dividuals residing in the country. The Regional Ethics Com-
mittee in Norway approved the study (2011/2272). No informed
consent was required for the analyses, as the records were
anonymized. To guide the reporting of this study, we used the
Strengthening the Reporting of Observational Studies in
Epidemiology statement (39).
Study Population and Exposure Groups
The study included 1,701,206 individuals born in Norway be-
tween 1967 and 1997 who were alive and living in Norway in
2015, the year of data linkage. This population consists of in-
dividuals mainly of European descent, with 8.2% of births
registered to mothers from non-European countries by 2015.
We defined adults with ADHD only (ADHD) as those who were
dispensed ADHD medication at any time between 2004 and
2015 (NorPD) or had an ADHD diagnosis (ICD-10 code F90),
but no ASD diagnosis, registered in the NPR during 2008 to
2015, and who were 18 years of age or older. The ADHD
medications were methylphenidate, racemic amphetamine,
dexamphetamine, and atomoxetine. Individuals prescribed
central stimulants for narcolepsy were excluded (see
Supplement for details).
Adults with ASD only (ASD) were defined as individuals with
an ASD diagnosis (ICD-10 codes F84.0–11F84.51F84.8–9)588 Biological Psychiatry October 15, 2019; 86:587–598 www.sobp.or(40,41) who were 18 years of age or older, were registered in
the NPR during 2008 to 2015, and had no ADHD diagnosis.
Adults (18 years of age or older) with both ADHD and ASD as
defined above comprised the combined group (ADHD1ASD).
The remaining population included all adults who were
neither dispensed ADHD medication registered in the NorPD
nor had an ADHD or ASD diagnosis registered in the NPR.
Parents of adults with and without ADHD/ASD were also
identified through the Medical Birth Registry of Norway and
included in the analyses to account for parental factors asso-
ciated with ADHD, ASD, and other psychiatric disorders (e.g.,
sociodemographic factors, pregnancy-related factors, parental
psychiatric disorders) and relatedness.
Outcome Diagnoses
We studied the following major comorbid psychiatric disorders
typically diagnosed in late adolescence and adulthood (42), all
registered in the NPR, at 18 years of age or older: anxiety
disorders (ICD-10 codes F40–F42); MDD (F32–F33); BD (F30–
F31); PDs (F60–F61), with a separate analysis on antisocial
personality disorder (F60.2) (only included in the main analyses
because of a small number of cases); SCZ (F20–F29); and SUD
(F10–F19). For BD, we also included those individuals who
were dispensed lithium during 2004 to 2015, according to
NorPD.
Summary Statistics From Large-Scale Genome-
wide Association Studies
Summary statistics from the large-scale genome-wide asso-
ciation studies (GWASs) for the psychiatric disorders examined
(10,43–51) were downloaded from the LD Hub GWAS share
center (http://ldsc.broadinstitute.org/gwashare/) (52). To date,
no GWAS has examined the genetics of individuals diagnosed
with both ADHD and ASD. Combining the existing data from
individual GWASs on ADHD and ASD, respectively, would
result in associations heavily biased toward the larger study.
Thus, we analyzed ADHD and ASD separately.
As not all data are publicly available, and no large-scale,
well-powered GWASs were performed on all disorders exam-
ined, we used some proxy traits. Owing to the lack of adequate
genetic data on PDs, we combined the data from the five
GWASs on the five traits in the NEO Personality Inventory
(NEO) (neuroticism, extraversion, openness to experience,
agreeableness, and conscientiousness) (48,53) using the in-
verse variance method in METAL software (54). As all five NEO
personality traits were analyzed in same-sized samples, there
was no bias toward any of the traits. We also used the trait
“antisocial behavior” as a proxy for antisocial personality dis-
order (49). As proxies for SUD, we used smoking behavior (ever
smoked vs. never smoked) (51) and alcohol dependence (50).
In all analyses, we restricted the examined data to single
nucleotide polymorphisms of good imputation quality (INFO
$0.8), minor allele frequency $1% (common variation), and
the data were derived from individuals of European descent
only.
Statistical Analyses
We estimated prevalence ratios (PRs) using Poisson regres-
sion with robust standard errors (55) to examine theg/journal




50 Yearsassociations of ADHD, ASD, and ADHD1ASD with other
psychiatric disorders, using the remaining adult population as
reference. To adjust for potential confounders, we performed
two regression models, which included the following cova-
riates: 1) model I, which included birth year, maternal marital
status, maternal age and paternal age in years at delivery,
parents’ highest attained level of education at record linkage,
the individual’s gestational age in weeks, and the individual’s
gestational age- and sex-specific birth weight Z scores (56);
and 2) model II, which included covariates of model I and
mothers’ and fathers’ psychiatric diagnoses, including ADHD
or any other psychiatric diagnosis from the NPR from 2008 to
2015 (for details about the covariates, see footnotes beneath
the tables and figures and in the Supplement). To account for
correlations between siblings, we used mother’s identification
number as a cluster variable in the analyses.
Analyses were performed on the total sample and stratified
by sex. Our main analyses were based on the multiplicative
scale using relative effect measures; however, when assessing
sex differences, we supplemented the analyses with absolute
effect measures. For this, we estimated prevalence differences
of psychiatric disorders between men and women with and
without ADHD, ASD, or ADHD1ASD using predicted preva-
lence from a Poisson regression model with adjustment for
birth year (5-year periods). Significance of interaction by sex on
the multiplicative scale was evaluated by comparing the
Poisson regression models with and without the interaction
term (sex 3 ADHD) included, tested by likelihood ratio tests,
and significance of interaction by sex on the additive scale was
evaluated using relative excess risk due to interaction (57).
Two-sided tests with a significance threshold of p , .05
were employed in all analyses.
Analyses were carried out with SPSS version 22.0 (IBM
Corp., Armonk, NY) and STATA intercooled version 14
(StataCorp, College Station, TX) from November 3, 2017, to
March 13, 2019.
Genetic correlations (rg) were calculated using linkage
disequilibrium score regression, which quantifies the similarities
in genetic architecture between two traits by evaluating the
relationship between single nucleotide polymorphism associa-
tion strengths and genetic linkage disequilibrium (8). Owing to
sample overlap between the examined datasets, the correlations
were calculatedwithout constraining the intercept. To calculate if
the genetic correlations in the ADHD group were significantly
different from those in the ASD group, we applied the following
formula: rg12 rg2ffiffiffiffiffiffiffiffiffiffiffi
a2 1b2
p , where rg1 refers to the genetic correlation
between a comorbidity and ADHD, rg2 refers to the genetic
correlation between the same comorbid disorder and ASD, a
refers to SE of the rg1 estimate, and b refers to the standard error
of the rg2 estimate. The significance was calculated using a two-
tailed Z test. To account for multiple testing, Bonferroni correc-
tion was applied to the significant threshold of .05, bringing the
adjusted significance threshold to .00625.Sensitivity Analyses
We conducted several sensitivity analyses to evaluate the
robustness of our results. We reran all the analyses 1)
excluding individuals with a diagnosis of intellectual disability,
2) excluding all with comorbid diagnoses of SCZ whenBiological Psyanalyzing BD and SUD, 3) excluding all individuals with SUD
when analyzing SCZ, and 4) including only individuals who had
their psychiatric diagnosis registered at least twice in the NPR.
Missing values in covariates (6% for gestational age and birth
weight Z scores, ,1% for other variables) were handled by
listwise deletion in the main analyses. In the sensitivity ana-
lyses, we also used multiple imputation with chained equations
(58) to evaluate possible bias due to missing information in
gestational age when adjusting for covariates. The outcome
variables, all specified covariates, and also birth weight,
maternal pre-eclampsia, and mother’s chronic diseases (yes/
no) were used for this information.
RESULTS
Study Population
Among the 1,701,206 individuals included in the study, we
identified 38,636 adults (2.3% of the population; 45% women)
with ADHD, 7528 adults (0.4%; 27.9% women) with ASD, 1467
adults (0.1%; 28.8% women) with ADHD1ASD, and 1,653,575
adults (97.2%; 49% women) in the remaining population. In
2015, the mean ages of individuals in the ADHD, ASD, and
ADHD1ASD groups were 31, 26, and 27 years of age,
respectively, compared with 33 years of age in the remaining
population (Table 1). Among parents, significantly more
mothers of individuals with ASD and ADHD1ASD had the
highest level of education compared with the ADHD group and
the remaining population, likely explained by the mothers of
individuals with ASD/ADHD1ASD having been born later in our
study period, in a time during which higher education was
more common. In addition, being diagnosed with at least one
psychiatric disorder was more prevalent among parents of
individuals in all exposure groups, compared with the
remaining population (Table 1).
Psychiatric Comorbidity in Adults With ADHD, ASD,
or ADHD1ASD
Comorbid psychiatric disorders were 2 to 14 times more
common in adults with ADHD, ASD, or ADHD1ASD than in the
remaining population (Table 2). Overall, the PRs differed
significantly between adults with ADHD and ASD for all psy-
chiatric disorders studied. Relative to the remaining popula-
tion, the association with BD was the strongest and the
association with MDD was the weakest in adults with ADHD
(PRBD, 7.1; 95% confidence interval [CI], 6.8–7.4; PRMDD, 3.7;
95% CI, 3.6–3.8), while the association with SCZ was the
strongest and the association with SUD was the weakest in
adults with ASD (PRSCZ, 13.9; 95% CI, 12.7–15.2; PRSUD, 1.9;
95% CI, 1.7–2.2) (Table 2, model II). The associations with
anxiety disorders, BD, MDD, PDs, and SUD were significantly
stronger in adults with ADHD than in adults with ASD (p , .001
for all), with SUD revealing a particularly pronounced difference
(PRADHD, 6.2 vs. PRASD, 1.9). The association with SCZ, how-
ever, was stronger in adults with ASD than in adults with ADHD
(PRASD, 13.9 vs. PRADHD, 4.4; p , .001).
In the ADHD1ASD group, the PRs ranged from 3.6 for MDD
(95% CI, 3.2–4.0) to 12.5 for SCZ (95% CI, 10.3–15.1) (Table 2,
model II). For all disorders, except MDD and SUD, associations
with ADHD1ASD were significantly stronger than for thosechiatry October 15, 2019; 86:587–598 www.sobp.org/journal 589
Table 1. Sample Characteristics of the 1,701,206 Adults in the Study Population, All Born From 1967 to 1997 and Followed
Until 2015
Variable ADHD ASD ADHD1ASD Remaining Population
Population 38,636 (2.3) 7528 (0.4) 1467 (0.1) 1,653,575 (97.2)
Women 17,393 (45.0), p , .001a 2099 (27.9), p = .491b 422 (28.8), p , .001c 809,962 (49.0), p , .001d
Male/Female Ratio 1.22 2.58 2.48 1.04
Age in 2015, Years 31.3 6 8.3, p , .001a 26.2 6 7.9, p = .99b 26.8 6 7.1, p , .001c 33.2 6 9.3, p , .001d
Maternal Age at Birth p , .001a p , .001b p , .001c p , .001d
,20 years 4417 (11.4) 372 (4.9) 107 (7.3) 112,674 (6.8)
20–24 years 13,587 (35.2) 1936 (25.7) 435 (29.7) 498,264 (30.1)
25–29 years 11,865 (30.7) 2539 (33.7) 525 (35.8) 575,743 (34.8)
30–34 years 6144 (15.9) 1747 (23.2) 279 (19.0) 327,637 (19.8)
35–39 years 2215 (5.7) 774 (10.3) 102 (7.0) 116,139 (7.0)
401 years 408 (1.1) 160 (2.1) 19 (1.3) 23,118 (1.4)
Paternal Age at Birth p , .001a p , .001b p , .001c p , .001d
,20 years 1054 (2.7) 75 (1.0) 21 (1.4) 24,546 (1.5)
20–24 years 9013 (23.3) 1093 (14.5) 267 (18.2) 302,939 (18.3)
25–29 years 12,941 (33.5) 2242 (29.8) 484 (33.0) 563,896 (34.1)
30–34 years 8728 (22.6) 2120 (28.2) 392 (26.7) 432,678 (26.2)
35–39 years 4086 (10.6) 1154 (15.3) 182 (12.4) 207,833 (12.6)
40–44 years 1621 (4.2) 519 (6.9) 78 (5.3) 76,947 (4.7)
45–49 years 489 (1.3) 171 (2.3) 25 (1.7) 24,796 (1.5)
501 years 183 (0.5) 70 (0.9) 3 (0.2) 8741 (0.5)
Missing 521 (1.4) 84 (1.1) 15 (1.0) 11,199 (0.7)
Maternal Marital Statusd p , .001a p , .007b p = .016c p , .001d
Single 6483 (16.8) 909 (12.1) 225 (15.3) 151,975 (9.2)
Married/cohabiting 31,122 (80.6) 6508 (86.5) 1220 (83.2) 1,482,685 (89.7)
Other 924 (2.4) 96 (1.3) 20 (1.4) 16,154 (1.0)
Missing 107 (0.3) 15 (0.2) 2 (0.1) 2761 (0.2)
Maternal Education Status p , .001a p = .169b p , .001c p , .001d
Low 13,498 (34.9) 1904 (25.3) 394 (26.9) 430,874 (26.1)
Middle 16,478 (42.7) 3022 (40.1) 583 (39.7) 768,773 (46.5)
High 8415 (21.8) 2565 (34.1) 488 (33.3) 447,380 (27.1)
Missing 245 (0.6) 37 (0.5) 2 (0.1) 6548 (0.4)
Paternal Education Status p , .001a p , .001b p , .001c p , .001d
Low 12,501 (32.4) 1639 (21.8) 388 (26.5) 381,154 (23.1)
Middle 18,626 (48.2) 3486 (46.3) 694 (47.3) 834,541 (50.5)
High 6475 (16.8) 2237 (29.7) 352 (24.0) 414,399 (25.1)
Missing 1034 (2.7) 166 (2.2) 33 (2.3) 23,481 (1.4)
Maternal Psychiatric Disorder p = .073a p , .001b p = .001c p , .001d
None 28,140 (72.8) 5557 (73.8) 1009 (68.8) 1,432,294 (86.6)
Paternal Psychiatric Disorder p , .001a p = .010b p = .492c p , .001d
None 31,478 (82.7) 6289 (84.7) 1189 (82.0) 1,479,367 (90.2)
Values are n (%) or mean 6 SD.
ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder.
aDifference between the ADHD and ASD cases (Pearson chi-square test and t test for equality of means).
bDifference between the ASD and ADHD1ASD cases (Pearson chi-square test and t test for equality of means).
cDifference between the ADHD and ADHD1ASD cases (Pearson chi-square test and t test for equality of means).
dDifference between cases relative to the comparison population (Pearson chi-square test and t test for equality of means).




50 Yearswith ADHD. For SCZ, associations with ADHD1ASD and ASD
were similar, and both were significantly stronger than asso-
ciations with ADHD (PRADHD1ASD, 12.5; 95% CI, 10.3–15.1;
PRASD, 13.9; 95% CI, 12.7–15.2; PRADHD, 4.4; 95% CI,
4.1–4.7; p , .001).590 Biological Psychiatry October 15, 2019; 86:587–598 www.sobp.orSex-Specific Results
When stratifying on sex, patterns of psychiatric comorbidity
corresponded with those in the total sample (Figure 1;
Supplemental Tables S2, S3). In both men and women, PR
estimates for SCZ were significantly larger in ASD org/journal
Table 2. Prevalence Ratios of Psychiatric Disorders Comparing Adults With and Without ADHD, ASD or ADHD1ASD, Based on 1.7 Million Individuals Born in
Norway (1967–1997) and Followed Until 2015
Psychiatric Disorders
(ICD-10 Codes)
Crude PR (95% CI)a PR Model I (95% CI)b PR Model II (95% CI)c
Remaining
Population ADHD ASD ADHD1ASD ADHD ASD ADHD1ASD ADHD ASD ADHD1ASD
Anxiety Disorders
(F40–F42)
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ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder; CI, confidence interval; ICD-10, International Classification of Diseases of the World Health Organization,
10th ed.; PR, prevalence ratio; ref, reference population.
aAdjusted for birth year (5-year groups, from 1967 to 1997, with 1967–1973 as the reference period).
bAdjusted for birth year, maternal marital status (single, married/cohabiting [reference], other), maternal and paternal education (low [,10 years], middle [10–12 years], and high [.12 years]
[reference]), maternal age (,20, 20–24, 25–29 [reference], 30–34, 35–39, 401 years of age) and paternal age (,20, 20–24, 25–29, 30–34 [reference], 35–39, 40–44, 45–49, 501 years of age) at
delivery, gestational age (,28, 28–31, 32–34, 35–36, 37–41 [reference], 421 weeks of age), and gestational age- and sex-specific birth weight Z scores (,22.0; 22.0 to 20.51; 20.5 to 0.5
[reference]; 0.51 to 2.0; 2.011).
cAdjusted for covariates as in model I and additionally adjusted for maternal and paternal psychiatric disorders (yes/no).
dDifference between the ADHD and the ASD cases (likelihood ratio test).
eDifference between the ASD and the ADHD1ASD cases (likelihood ratio test).
fDifference between the ADHD and the ADHD1ASD cases (likelihood ratio test).
























































































Figure 1. Prevalence ratios of psychiatric disorders in adults with attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), or
ADHD1ASD relative to the remaining population, by sex. Log scale, 95% confidence interval, error bars. Adjusted for birth year (5-year groups, from 1967 to
1997, with 1967–1973 as the reference), maternal marital status (single, married/cohabiting [reference], other), maternal and paternal education (low [,10
years], middle [10–12 years] and high [.12 years] [reference]), maternal age (,20, 20–24, 25–29 [reference], 30–34, 35–39, 401 years of age) and paternal age
(,20, 20–24, 25–29, 30–34 [reference], 35–39, 40–44, 45–49, 501 years of age) at delivery, gestational age (,28, 28–31, 32–34, 35–36, 37–41 [reference], 421
weeks of age), gestational age- and sex-specific birth weight Z scores (,22.0; 22.0 to 20.51; 20.5 to 0.5 [reference]; 0.51 to 2.0; 2.011), and maternal and
paternal psychiatric disorders (yes/no). BD, bipolar disorder; MDD, major depressive disorder; PD, personality disorders; schizophrenia, schizophrenia
spectrum disorder; SUD, substance use disorder.




50 YearsADHD1ASD than in ADHD, while for SUD, estimates were
significantly larger for ADHD or ADHD1ASD than for ASD. For
anxiety disorders, the PR estimates were significantly larger in
men than in women for all exposure groups, and for SCZ, the
PR was significantly larger in women with ASD than in men
with ASD.
When evaluating associations and interactions on the ad-
ditive scale, sex differences were more pronounced, and the
prevalence difference estimates were significantly different for
all the disorders in women and men with ADHD but for only
three disorders in men and women with ASD (Figure 2;
Supplemental Table S4). Further, the associations were592 Biological Psychiatry October 15, 2019; 86:587–598 www.sobp.orreversed, and prevalence of most psychiatric disorders
increased more in women than in men in all exposure groups
except SUD and SCZ, in which men in all exposure groups
showed the highest prevalence increase.Genetic Correlations
As shown in Figure 3, the patterns of genetic correlations (rg)
were similar to those of the PRs for psychiatric comorbidities
based on the epidemiological data. The two proxies for SUD
revealed significantly stronger correlations with ADHD than
with ASD (Figure 3, right panel; Supplemental Table S5). Forg/journal
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Figure 2. Prevalence difference of psychiatric disorders in adults with attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD),
ADHD1ASD relative to the remaining population, by sex. Prevalence difference, 95% confidence interval, error bars, analog scale. Adjusted for birth year
(5-year groups, from 1967 to 1997). BD, bipolar disorder; MDD, major depressive disorder; PD, personality disorders; schizophrenia, schizophrenia spectrum
disorder; SUD, substance use disorder.




50 YearsSCZ, the rg estimate for ASD was almost twice as large as that
for ADHD (rg(ASD1SCZ): 0.211 [SE: 0.048, p , .0001];
rg(ADHD1SCZ): 0.127 [SE: 0.036, p = .0004]), but this difference
was not statistically significant (p = .16). The differences in
genetic correlations between ADHD and ASD with the exam-
ined comorbid disorders were statistically significant only for
the SUD proxies and for the NEO personality dimensional traits
(Supplemental Table S5).
Sensitivity Analyses
When we excluded individuals with intellectual disability, the
results changed only for ASD, in which the PR for SCZ
increased slightly (PRcrude, 15.1; 95% CI, 13.9–16.4; PRsensitivity,
16.5; 95% CI, 15.1–18.1). For the ADHD and the ADHD1ASD
groups, there were no substantial changes. All the otherBiological Psysensitivity analyses yielded results that were very similar to
those of the main analyses (Supplemental Tables S6, S7).
DISCUSSION
In this first nationwide, population-based study combining
epidemiological data on adults with ADHD only, ASD only, or
both ADHD and ASD, together with corresponding genetic
data, we found different patterns of psychiatric comorbidities
between the groups, overall and also when stratifying by sex.
These patterns were also reflected in the genetic correlations;
however, only proxies for two of the six traits showed a sig-
nificant difference between ADHD and ASD. We also found
that adults with both ADHD and ASD have severe additional
psychiatric morbidity relative to adults with either ADHD or
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Figure 3. (Left panel) The pattern of prevalence ratios of psychiatric comorbidity in adults with attention-deficit/hyperactivity disorder (ADHD) (n = 38,636) or
autism spectrum disorder (ASD) (n = 7528) observed in this study and (right panel) genetic correlations (rg) calculated from genome-wide association studies.
(Left panel) Prevalence ratio, model II, log-scale, 95% confidence interval, error bars. Adjusted for birth year (5-year groups, from 1967 to 1997, with 1967–1973
as the reference), maternal marital status (single, married/cohabiting [reference], other), maternal and paternal education (low [,10 years], middle [10–12 years]
and high [.12 years] [reference]), maternal age (,20, 20–24, 25–29 [reference], 30–34, 35–39, 401 years of age) and paternal age (,20, 20–24, 25–29, 30–34
[reference], 35–39, 40–44, 45–49, 501 years of age) at delivery, gestational age (,28, 28–31, 32–34, 35–36, 37–41 [reference], 421 weeks of age), gestational
age- and sex-specific birth weight Z scores (,22.0; 22.0 to 20.51; 20.5 to 0.5 [reference]; 0.51 to 2.0; 2.011), and maternal and paternal psychiatric dis-
orders (yes/no). (Right panel) Genetic correlations, rg, linear scale, SE bars, with “Ever vs Never Smoked” and “Alcohol Dependence” as proxies for substance
use disorder, and “NEO–5–Personality Traits” as proxy for personality disorder.




50 YearsWhen comparing ADHD and ASD in our epidemiological
data, we observed significant differences in the associations
with all psychiatric comorbidities examined, with individual
estimates being consistent with previous studies
(11–13,15,24,30–32). The most marked differences were found
for SCZ and SUD, in which SCZ was more common in adults
with ASD and SUD was more common in adults with ADHD.
Associations with anxiety disorders, BD, and PDs were
strongest in adults with both ADHD and ASD, indicating that
this group of adults has more severe impairments than those
with ADHD or ASD only (59). This is supported by previous
studies in children (32,60). Further, we found that adults with
both ADHD and ASD had a similar increase in risk for SCZ as
that for adults with ASD only, which, as far as we know, has not
been shown before. To our knowledge, only one other
population-based study reported the prevalence of psychiatric
disorders among individuals with ADHD, ASD, or ADHD1ASD
compared with unaffected individuals in the same population
(33). However, this population was young (mean age ranging
from 13.6 to 18.3 years) and had not reached the typical age of
onset for most psychiatric disorders (42). The reported esti-
mates were, therefore, likely to be biased.
With regard to the genetic correlations, the patterns were
similar to those we observed in the epidemiological data, and
two—the SUD proxies and NEO personality traits—revealed
significant differences in their correlations with ADHD and
ASD. The genetic correlation (rg) between ADHD and ASD has594 Biological Psychiatry October 15, 2019; 86:587–598 www.sobp.orbeen estimated to be 0.36 (10), indicating shared genetic
etiology between them. Nonetheless, it is conceivable that
their polygenic architecture is still different, as supported by
our epidemiological observation of significantly different pat-
terns of comorbidities between these two disorders. It has also
been shown that individuals with various clinical manifesta-
tions of ASD reveal distinct loads of genetic variants associ-
ated with this disorder (10,61).
Etiological similarities, as well as differences between ADHD
and ASD, can be further and more specifically evaluated by
examining their symptom dimensions, each of which may have
independent and different explanatory values for the clinical
diagnoses of ADHD, ASD, and their comorbidities. Ghirardi
et al. (28), for example, have reported that the symptoms of
hyperactivity/impulsivity (ADHD) show different levels of ge-
netic correlation with symptoms of ASD (e.g., a strong genetic
correlation with repetitive and restricted behaviors [ASD] and a
weak correlation with social interaction and communication).
Our current diagnostic criteria are based on clinically observed
aggregates of symptoms but may not relate to distinct un-
derlying biological pathways. Hence, well-powered GWASs on
clearly defined specific psychiatric phenotypes and narrower
symptom domains are needed to uncover the biological
mechanisms underlying the multifaceted etiologies of ADHD
and ASD.
Apart from genetics, the observed differences in patterns of
comorbidities between ADHD and ASD may also be explainedg/journal




50 Yearsby diagnostic factors. Diagnosing psychiatric comorbidities in
adults with ASD is difficult, as many diagnostic tools are not
customized for these individuals (31,62). In addition, clinicians
may not look for additional psychiatric disorders in ASD pa-
tients and explain their symptoms as part of the underlying
ASD (32), i.e., diagnostic overshadowing (63). Further, on a
more psychological level, even if individuals with ADHD or ASD
often experience peer rejection and relational problems (64,65),
individuals with ASD are diagnostically defined by their strug-
gle to communicate and hence are less able to communicate
their problems because of their large impairments (66,67). This
may contribute to a lower level of diagnosed psychiatric
comorbidities in individuals with ASD.
The sex differences in risk of psychiatric comorbidities were
different among adults with ADHD and ASD, on both the
relative and absolute scales. The present findings for adults
with ADHD are also presented in our previous publication (19)
and were confirmed by a recent Swedish study (68). Sex dif-
ferences are strongly dependent on the scale used for ana-
lyses, with stronger associations for most psychiatric
comorbidities in men than in women on the relative scale and
stronger associations in women than in men on the absolute
scale. This may be explained by the lower prevalence in psy-
chiatric disorders among men than women in the reference
group, which has a profound influence on the relative effect
measures but not on the risk differences. We suggest that the
smaller sex differences observed in adults with ASD than
ADHD may partly be explained by the larger male/female ratio
in adults with ASD and partly by women with ASD struggling
more to communicate internalizing symptoms than women
with ADHD (69,70).
The behavioral patterns in the individuals of the two
phenotypically different disorders also lead to different in-
teractions with their environments. The differences in the as-
sociations with SUD between ADHD and ASD may partly be
due to the ADHD-associated novelty seeking and impulsive
behavior, increasing the risk of developing SUD to a larger
degree in ADHD than in ASD, in which a rigid and norm-abiding
behavior, with limited social contact, may be relatively pro-
tective (30,71,72). Thus, both genetic and environmental risk
factors, as well as their interactions, may alter the expression
of genes and affect the structure and function of molecular
networks in the brain, thereby modifying the risk of ADHD and
ASD (32).Strengths and Limitations
To our knowledge, this is the largest population-based study
comparing psychiatric comorbidity in adults with ADHD, ASD,
or both ADHD and ASD conducted so far. The analyses were
also stratified according to sex and included genetic correla-
tions in the interpretation. We used data from nationwide,
population-based registries with compulsory notification, thus
reducing selection bias to a minimum. As our patient groups
were large enough to allow us to study individuals with either
ADHD alone or ASD alone, or both ADHD and ASD, we were
able to study differences between more homogeneous groups.
We designed our study specifically to examine an adult
population, allowing all participants to reach the typical age of
diagnosis of the conditions investigated (42). Notably, thisBiological Psystudy covers the first birth cohort for which ASD became
prevalent enough in adulthood to enable such a study to be
performed.
In Norway, formal diagnoses of ASD and ADHD, and
pharmacological treatment of ADHD, are always based on
clinical evaluation by specialists. Thus, identification of ADHD
and ASD cases was not based solely on symptom scores or
self-reports. We chose to identify the ADHD cases either by a
dispensed prescription of ADHD medication from the NorPD or
by an ADHD diagnosis from the NPR, similar to other Scan-
dinavian studies (22,73–75). ASD, BD, and SCZ diagnoses in
the NPR have been validated with good results (36,76), sug-
gesting acceptable validity for other NPR-registered psychi-
atric diagnoses as well. However, we cannot exclude a
possible misdiagnosis of SCZ and ASD. Our definition of BD
was also based on dispensed lithium, a medication mainly
used for treating BD.
Limitations include the fact that our analyses were cross-
sectional and based on data registered from 2004 to 2015
(NorPD) and from 2008 to 2015 (NPR), preventing the exami-
nation of temporal relations. However, as ADHD and ASD are
defined as neurodevelopmental disorders with an onset in
childhood, we assume that they were present before the co-
morbid psychiatric disorders, all typically diagnosed in late
adolescence and adulthood (42).
Up to 2013, an ASD diagnosis would preclude a diagnosis
ADHD according to the DSM-IV and ICD-10 (77,78). This may
have affected the diagnostic procedures and hindered clini-
cians from diagnosing both disorders if the criteria for ASD
were fulfilled. However, clinical practice has not adhered
strictly to these criteria, as growing evidence supported the
importance of diagnosing both conditions when present to
provide the best treatment (31).
Further, it may be argued that adults with ADHD or ASD
could more easily get other psychiatric diagnoses because
they are already in touch with the health care system (79).
However, all adults with severe psychiatric disorders are likely
to be in touch with secondary health care throughout life, in-
dependent of underlying neurodevelopmental disorders (80).
With regard to the genetic correlations, it is important to
note that their estimations are highly dependent on the sample
size of the utilized GWAS. In addition, because there are no
large-scale GWASs with freely available summary statistics for
some of the examined comorbidities, proxy phenotypes were
examined. Furthermore, patients’ comorbidities are not always
taken into account in the genetic studies, although individuals
with known combined ADHD and ASD were excluded from
some studies (43). Currently, psychiatric genetics are lacking
GWASs on patients with comorbidities or with specific symp-
toms of psychiatric disorders, which limits our ability to
examine the genetic variability that may be responsible for the
diverse clinical landscape of psychiatric disorders.Conclusions
In conclusion, our study provides robust and representative
estimates of differences in psychiatric comorbidities among
adults diagnosed with ADHD, ASD, or ADHD1ASD. With the
results from analyses of genetic correlations, this finding
contributes to our understanding of these disorders as beingchiatry October 15, 2019; 86:587–598 www.sobp.org/journal 595




50 Yearsdistinct neurodevelopmental disorders with partly shared
common genetic factors. Clinicians should be aware of the
overall high level of comorbidity in adults with ADHD, ASD, or
ADHD1ASD and of the distinct patterns of psychiatric
comorbidities to detect these conditions and offer early treat-
ment. It is also important to take into account the observed sex
differences. The distinct comorbidity patterns may provide
further information regarding etiologic research on biological
mechanisms underlying the pathophysiology of these neuro-
developmental disorders.
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